share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  04/30 16:59
Moomoo AI 已提取核心訊息
On April 29, 2024, ProSomnus, Inc., a medical technology company, announced the issuance and sale of an additional $2 million in Senior Secured Convertible Notes due December 6, 2025, to certain existing investors. This follows a previous issuance of the same amount on April 19, 2024. The notes are part of an agreement under an Indenture dated December 6, 2022, and supplemented by two subsequent indentures. The notes, bearing a 9% annual interest rate, are guaranteed by subsidiary guarantors and secured by the company's assets. This financial move comes after the Nasdaq Stock Market LLC filed to delist ProSomnus' common stock and warrants on April 24, 2024, due to non-compliance with certain listing requirements. Since April 18, 2024, the company's securities have been trading over-the-counter under the symbols 'OSAP' and 'OSAPW'. The delisting from Nasdaq is expected to have no practical effect on the current over-the-counter trading.
On April 29, 2024, ProSomnus, Inc., a medical technology company, announced the issuance and sale of an additional $2 million in Senior Secured Convertible Notes due December 6, 2025, to certain existing investors. This follows a previous issuance of the same amount on April 19, 2024. The notes are part of an agreement under an Indenture dated December 6, 2022, and supplemented by two subsequent indentures. The notes, bearing a 9% annual interest rate, are guaranteed by subsidiary guarantors and secured by the company's assets. This financial move comes after the Nasdaq Stock Market LLC filed to delist ProSomnus' common stock and warrants on April 24, 2024, due to non-compliance with certain listing requirements. Since April 18, 2024, the company's securities have been trading over-the-counter under the symbols 'OSAP' and 'OSAPW'. The delisting from Nasdaq is expected to have no practical effect on the current over-the-counter trading.
2024年4月29日，醫療技術公司ProSomnus, Inc. 宣佈向某些現有投資者額外發行和出售2025年12月6日到期的200萬美元優先擔保可轉換票據。在此之前，上次於2024年4月19日發行了相同金額的股票。這些票據是2022年12月6日契約協議的一部分，並由隨後的兩份契約予以補充。這些票據的年利率爲9％，由子公司擔保人擔保，並由公司的資產擔保。這一財務舉措是在納斯達克股票市場有限責任公司因不遵守某些上市要求而於2024年4月24日申請將Prosomnus的普通股和認股權證退市之後採取的。自2024年4月18日以來，該公司的證券一直在場外交易，代碼爲 “OSAP” 和 “OSAPW”。從納斯達克退市預計不會對當前的場外交易產生任何實際影響。
2024年4月29日，醫療技術公司ProSomnus, Inc. 宣佈向某些現有投資者額外發行和出售2025年12月6日到期的200萬美元優先擔保可轉換票據。在此之前，上次於2024年4月19日發行了相同金額的股票。這些票據是2022年12月6日契約協議的一部分，並由隨後的兩份契約予以補充。這些票據的年利率爲9％，由子公司擔保人擔保，並由公司的資產擔保。這一財務舉措是在納斯達克股票市場有限責任公司因不遵守某些上市要求而於2024年4月24日申請將Prosomnus的普通股和認股權證退市之後採取的。自2024年4月18日以來，該公司的證券一直在場外交易，代碼爲 “OSAP” 和 “OSAPW”。從納斯達克退市預計不會對當前的場外交易產生任何實際影響。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息